( 2 ) launch and commercialize the forecyte breast aspirator in the eu : we received ce certificate of conformity from our notified body for the forecyte breast aspirator and collection kits in october 2014 and in march 2015 began the launch of this device in the eu and the countries of the european free trade association ( efta ) , focusing initially on the netherlands , germany , switzerland , and the united kingdom . ( 3 ) maximize total gross revenue from our products and services : we plan to grow our revenue by selling our products and promoting the tests currently being offered by the nrlbh , including naf cytology tests and pharmacogenomics tests , and by developing and commercializing additional laboratory tests . we launched the pharmacogenomics test in october 2014 and processed and reported 527 tests through december 31 , 2014 . ( 4 ) begin one or more clinical studies using our devices and potential pharmaceutical therapy : we plan to develop a pharmaceutical to be delivered through our patented microcatheters , initially to treat dcis . we also plan to develop a pharmaceutical to treat one or more conditions detected by the laboratory tests conducted on the naf specimens collected with our breast aspirator devices . in this fashion , our devices and laboratory tests can be used as companion diagnostics to the therapies we plan to develop . we expect that these therapies and companion diagnostics will initially target dcis , ductal hyperplasia , ped and or high risk women and will require lengthy and costly clinical trials that we will undertake only with input and direction from the fda . many of our medical devices and the nrlbh 's laboratory services , as well as the breast health companion diagnostic systems , are currently under development and , if required by fda , we must receive additional regulatory clearances and or approvals prior to marketing and commercialization . our medical devices our medical devices being commercialized and under development include our breast aspirators , intraductal microcatheters and various tools for breast surgeons . 52 our forecyte breast aspirator ( formerly called the masct system ) was launched in a “ field experience ” trial in the u.s. in 2012 and nationally in the beginning of 2013. in october 2013 , we voluntarily recalled the masct system to address concerns raised by the fda in a warning letter we received in february 2013. in december 2013 , we submitted a premarket notification to the fda for a 510 ( k ) clearance for the forecyte breast aspirator , and in september 2014 the fda determined that the forecyte breast aspirator is not substantially equivalent to its predicate device which means that as of the date of this report the device is not cleared by the fda for marketing in the united states . we are currently evaluating the feedback we received from the fda and the u.s. regulatory pathway for the forecyte device in the united states . the forecyte breast aspirator device has received the ce mark and we began the launch of this device in the eu and efta countries in march 2015 , initially focusing on the netherlands , germany , switzerland , and the united kingdom . this device is being manufactured in asia and we have contracted with rhenus logistics for logistical and other services in european and other markets . the fullcyte breast aspirator was launched in the united states in march 2015. this device is marketed in the u.s. by direct sales personnel as well as third party distributors , including fisher healthcare , a division of thermo fisher scientific , and henry schein medical . our intraductal microcatheters are being developed for the collection of ductal lavage fluid for cytology testing and for the potential administration of pharmaceutical therapeutics . our clia-certified laboratory – the nrlbh the nrlbh has been certified pursuant to the clinical laboratory improvement amendments , or clia . clia certification is legally required to receive reimbursement from federal or state medical benefit programs , like medicare and medicaid , and is a practical requirement for most third party insurance benefit programs . the nrlbh is also accredited by the college of american pathologists ( cap ) , which is awarded to facilities that meet the highest standards of excellence in quality laboratory practices . the nrlbh is permitted to accept naf and pharmacogenomics samples from all 50 states under its clia certification , its state licenses , or , in new york under recognized exemption provisions while its license application is pending . the nrlbh markets and sells its tests primarily through third party sales and marketing organizations , such as bioventive , inc. the nrlbh currently offers two tests : naf cytology tests and pharmacogenomics tests . the pharmacogenomics tests were launched in october 2014. the naf cytology testing was offered beginning in 2012. our therapeutic program under development we plan to develop certain of our medical devices and laboratory tests so that they can be used as companions to pharmaceutical therapies . for example , we plan to develop our medical devices and laboratory tests as companion diagnostics to pharmaceutical therapies to treat women at high risk of breast cancer and for the treatment of conditions known as proliferative epithelial disease ( ped ) . these programs are in the early pre-clinical stage and will require testing and approval and or clearance from the fda prior to commercialization . our intraductal treatment research program comprises our patented microcatheter-delivery technology and pharmaceutical formulations for the intraductal treatment of breast pre-cancerous changes and dcis . the method uses our mammary ductal microcatheter system to administer proprietary pharmaceutical formulations into milk ducts that display pre-cancerous changes , or dcis , with high local concentrations of the drugs in order to promote greater efficacy and limited systemic exposure , potentially lowering the overall toxicity of the treatment . story_separator_special_tag , an increase of $ 13,914 , or 1 % , from $ 1,257,791 for the year ended december 31 , 2013. selling expenses for the year ended december 31 , 2014 consisted primarily of $ 216,391 in selling and marketing professional fees , $ 409,625 in compensation expenses , and $ 610,774 in advertisement and were comparable with prior year 's expenses . we expect that our selling expenses will increase in the foreseeable future , as we build a sales force in the united states and outside the united states to support the launch and commercialization of the forecyte and fullcyte breast aspirators and our laboratory service offerings . selling expenses may also increase as we market and sell the services offered by the nrlbh , including naf cytology tests , pharmacogenomics tests and potentially other tests . general and administrative expenses : g & a expenses for the year ended december 31 , 2014 were $ 8,625,917 , an increase of $ 67,082 , or 0.8 % from $ 8,558,835 for the same period in 2013. g & a expenses consists primarily of personnel and related benefit costs , facilities , professional services , insurance , and public company related expenses . the increase was primarily attributable to a $ 1,773,876 increase in personnel costs and legal expenses in 2014 attributed to ongoing regulatory fees and shareholders ' litigation , offset by a reduction in expenses associated with our 2013 product recall for approximately $ 449,610 , $ 975,068 in professional fees , and $ 291,484 in advertising . we expect our g & a expenses to grow as we hire additional administrative and manufacturing personnel to prepare for and execute on the launch of the forecyte breast aspirator and fullcyte breast aspirator , pharmacogenomics testing and our other products and services under development and as we incur additional costs associated with being a publicly traded company . research and development expenses : r & d expenses for the year ended december 31 , 2014 were $ 2,577,465 , an increase of $ 1,472,355 , or 133 % , from the year ended december 31 , 2013. the increase in r & d expenses in 2014 is attributed to additional r & d expenditures on the development of our new products and tests in the pipeline , including the nextcyte test , fullcyte microcatheters and fullcyte breast aspirator . we expect that our r & d expenses will continue to increase throughout 2015 as we add additional full time employees and incur additional costs to continue the development of our products and services under development , including the development of a potential pharmaceutical and conducting one or more clinical studies . 56 impairment of intangible assets : during the year ended december 31 , 2014 , we recorded an impairment charge of $ 2,352,626 for certain intangible assets purchased in the acueity transaction in 2012. as a result of changes in our plans to develop and invest further in the acueity assets , we determined that the assets were impaired and wrote them down to the estimated fair value as of december 31 , 2014. no impairments of intangible assets were recorded during the year ended december 31 , 2013. story_separator_special_tag width : 3 % `` > the time and expense needed to continue the launch and commercialization of the forecyte and fullcyte breast aspirators ; the expense associated with building a network of independent sales representatives to market the forecyte and fullcyte breast aspirators , pharmacogenomics tests , naf cytology tests , and our planned therapeutic programs ; and the degree and speed of patient and physician acceptance of our products and the degree to which third party payors approve the tests for reimbursement . 57 additional funding may not be available to us on acceptable terms or at all . in addition , the terms of any financing may adversely affect the holdings or the rights of our stockholders . for example , if we raise additional funds by issuing equity securities or by selling debt securities , if convertible , further dilution to our existing stockholders would result . to the extent our capital resources are insufficient to meet our future capital requirements , we will need to finance our future cash needs through public or private equity offerings , collaboration agreements , debt financings or licensing arrangements . if adequate funds are not available , we may be required to terminate , significantly modify or delay our development programs , reduce our planned commercialization efforts , or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently . further , we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable . off-balance sheet arrangements we do not currently have , nor have we ever had , any relationships with unconsolidated entities or financial partnerships , such as entities often referred to as structured finance or special purpose entities , established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes . in addition , we do not engage in trading activities involving non-exchange traded contracts . recent accounting pronouncements in may 2014 , the financial accounting standards board ( the “ fasb ” ) issued accounting standards update ( “ asu ” ) no . 2014-09 , revenue from contracts with customers : topic 606 ( “ asu 2014-09 ” ) , to supersede nearly all existing revenue recognition guidance under u.s. gaap . the core principle of asu 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services . asu 2014-09 defines a five step process to achieve this core principle and , in doing so

liquidity and capital resources we have a history of operating losses as we have focused our efforts on raising capital and building the masct system . the company 's consolidated financial statements are prepared using generally accepted accounting principles in the united states of america applicable to a going concern , which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business . the company has incurred net losses and negative operating cash flows since inception . for the year ended december 31 , 2014 , the company recorded a net loss of approximately $ 14.6 million and used approximately $ 10.5 million of cash in operating activities . as of december 31 , 2014 , the company had approximately $ 8.5 million in cash and cash equivalents and working capital of approximately $ 6.9 million . the company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern . the ability of the company to continue as a going concern is dependent on the company obtaining adequate capital to fund operating losses until it becomes profitable . the company can give no assurances that any additional capital that it is able to obtain , if any , will be sufficient to meet its needs , or that any such financing will be obtainable on acceptable terms . if the company is unable to obtain adequate capital , it could be forced to cease operations or substantially curtail is commercial activities . these conditions raise substantial doubt as to the company 's ability to continue as a going concern . the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the company be unable to continue as a going concern .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have a history of operating losses as we have focused our efforts on raising capital and building the masct system . the company 's consolidated financial statements are prepared using generally accepted accounting principles in the united states of america applicable to a going concern , which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business . the company has incurred net losses and negative operating cash flows since inception . for the year ended december 31 , 2014 , the company recorded a net loss of approximately $ 14.6 million and used approximately $ 10.5 million of cash in operating activities . as of december 31 , 2014 , the company had approximately $ 8.5 million in cash and cash equivalents and working capital of approximately $ 6.9 million . the company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern . the ability of the company to continue as a going concern is dependent on the company obtaining adequate capital to fund operating losses until it becomes profitable . the company can give no assurances that any additional capital that it is able to obtain , if any , will be sufficient to meet its needs , or that any such financing will be obtainable on acceptable terms . if the company is unable to obtain adequate capital , it could be forced to cease operations or substantially curtail is commercial activities . these conditions raise substantial doubt as to the company 's ability to continue as a going concern . the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the company be unable to continue as a going concern .
```    
 Suspicious Activity Report : ( 2 ) launch and commercialize the forecyte breast aspirator in the eu : we received ce certificate of conformity from our notified body for the forecyte breast aspirator and collection kits in october 2014 and in march 2015 began the launch of this device in the eu and the countries of the european free trade association ( efta ) , focusing initially on the netherlands , germany , switzerland , and the united kingdom . ( 3 ) maximize total gross revenue from our products and services : we plan to grow our revenue by selling our products and promoting the tests currently being offered by the nrlbh , including naf cytology tests and pharmacogenomics tests , and by developing and commercializing additional laboratory tests . we launched the pharmacogenomics test in october 2014 and processed and reported 527 tests through december 31 , 2014 . ( 4 ) begin one or more clinical studies using our devices and potential pharmaceutical therapy : we plan to develop a pharmaceutical to be delivered through our patented microcatheters , initially to treat dcis . we also plan to develop a pharmaceutical to treat one or more conditions detected by the laboratory tests conducted on the naf specimens collected with our breast aspirator devices . in this fashion , our devices and laboratory tests can be used as companion diagnostics to the therapies we plan to develop . we expect that these therapies and companion diagnostics will initially target dcis , ductal hyperplasia , ped and or high risk women and will require lengthy and costly clinical trials that we will undertake only with input and direction from the fda . many of our medical devices and the nrlbh 's laboratory services , as well as the breast health companion diagnostic systems , are currently under development and , if required by fda , we must receive additional regulatory clearances and or approvals prior to marketing and commercialization . our medical devices our medical devices being commercialized and under development include our breast aspirators , intraductal microcatheters and various tools for breast surgeons . 52 our forecyte breast aspirator ( formerly called the masct system ) was launched in a “ field experience ” trial in the u.s. in 2012 and nationally in the beginning of 2013. in october 2013 , we voluntarily recalled the masct system to address concerns raised by the fda in a warning letter we received in february 2013. in december 2013 , we submitted a premarket notification to the fda for a 510 ( k ) clearance for the forecyte breast aspirator , and in september 2014 the fda determined that the forecyte breast aspirator is not substantially equivalent to its predicate device which means that as of the date of this report the device is not cleared by the fda for marketing in the united states . we are currently evaluating the feedback we received from the fda and the u.s. regulatory pathway for the forecyte device in the united states . the forecyte breast aspirator device has received the ce mark and we began the launch of this device in the eu and efta countries in march 2015 , initially focusing on the netherlands , germany , switzerland , and the united kingdom . this device is being manufactured in asia and we have contracted with rhenus logistics for logistical and other services in european and other markets . the fullcyte breast aspirator was launched in the united states in march 2015. this device is marketed in the u.s. by direct sales personnel as well as third party distributors , including fisher healthcare , a division of thermo fisher scientific , and henry schein medical . our intraductal microcatheters are being developed for the collection of ductal lavage fluid for cytology testing and for the potential administration of pharmaceutical therapeutics . our clia-certified laboratory – the nrlbh the nrlbh has been certified pursuant to the clinical laboratory improvement amendments , or clia . clia certification is legally required to receive reimbursement from federal or state medical benefit programs , like medicare and medicaid , and is a practical requirement for most third party insurance benefit programs . the nrlbh is also accredited by the college of american pathologists ( cap ) , which is awarded to facilities that meet the highest standards of excellence in quality laboratory practices . the nrlbh is permitted to accept naf and pharmacogenomics samples from all 50 states under its clia certification , its state licenses , or , in new york under recognized exemption provisions while its license application is pending . the nrlbh markets and sells its tests primarily through third party sales and marketing organizations , such as bioventive , inc. the nrlbh currently offers two tests : naf cytology tests and pharmacogenomics tests . the pharmacogenomics tests were launched in october 2014. the naf cytology testing was offered beginning in 2012. our therapeutic program under development we plan to develop certain of our medical devices and laboratory tests so that they can be used as companions to pharmaceutical therapies . for example , we plan to develop our medical devices and laboratory tests as companion diagnostics to pharmaceutical therapies to treat women at high risk of breast cancer and for the treatment of conditions known as proliferative epithelial disease ( ped ) . these programs are in the early pre-clinical stage and will require testing and approval and or clearance from the fda prior to commercialization . our intraductal treatment research program comprises our patented microcatheter-delivery technology and pharmaceutical formulations for the intraductal treatment of breast pre-cancerous changes and dcis . the method uses our mammary ductal microcatheter system to administer proprietary pharmaceutical formulations into milk ducts that display pre-cancerous changes , or dcis , with high local concentrations of the drugs in order to promote greater efficacy and limited systemic exposure , potentially lowering the overall toxicity of the treatment . story_separator_special_tag , an increase of $ 13,914 , or 1 % , from $ 1,257,791 for the year ended december 31 , 2013. selling expenses for the year ended december 31 , 2014 consisted primarily of $ 216,391 in selling and marketing professional fees , $ 409,625 in compensation expenses , and $ 610,774 in advertisement and were comparable with prior year 's expenses . we expect that our selling expenses will increase in the foreseeable future , as we build a sales force in the united states and outside the united states to support the launch and commercialization of the forecyte and fullcyte breast aspirators and our laboratory service offerings . selling expenses may also increase as we market and sell the services offered by the nrlbh , including naf cytology tests , pharmacogenomics tests and potentially other tests . general and administrative expenses : g & a expenses for the year ended december 31 , 2014 were $ 8,625,917 , an increase of $ 67,082 , or 0.8 % from $ 8,558,835 for the same period in 2013. g & a expenses consists primarily of personnel and related benefit costs , facilities , professional services , insurance , and public company related expenses . the increase was primarily attributable to a $ 1,773,876 increase in personnel costs and legal expenses in 2014 attributed to ongoing regulatory fees and shareholders ' litigation , offset by a reduction in expenses associated with our 2013 product recall for approximately $ 449,610 , $ 975,068 in professional fees , and $ 291,484 in advertising . we expect our g & a expenses to grow as we hire additional administrative and manufacturing personnel to prepare for and execute on the launch of the forecyte breast aspirator and fullcyte breast aspirator , pharmacogenomics testing and our other products and services under development and as we incur additional costs associated with being a publicly traded company . research and development expenses : r & d expenses for the year ended december 31 , 2014 were $ 2,577,465 , an increase of $ 1,472,355 , or 133 % , from the year ended december 31 , 2013. the increase in r & d expenses in 2014 is attributed to additional r & d expenditures on the development of our new products and tests in the pipeline , including the nextcyte test , fullcyte microcatheters and fullcyte breast aspirator . we expect that our r & d expenses will continue to increase throughout 2015 as we add additional full time employees and incur additional costs to continue the development of our products and services under development , including the development of a potential pharmaceutical and conducting one or more clinical studies . 56 impairment of intangible assets : during the year ended december 31 , 2014 , we recorded an impairment charge of $ 2,352,626 for certain intangible assets purchased in the acueity transaction in 2012. as a result of changes in our plans to develop and invest further in the acueity assets , we determined that the assets were impaired and wrote them down to the estimated fair value as of december 31 , 2014. no impairments of intangible assets were recorded during the year ended december 31 , 2013. story_separator_special_tag width : 3 % `` > the time and expense needed to continue the launch and commercialization of the forecyte and fullcyte breast aspirators ; the expense associated with building a network of independent sales representatives to market the forecyte and fullcyte breast aspirators , pharmacogenomics tests , naf cytology tests , and our planned therapeutic programs ; and the degree and speed of patient and physician acceptance of our products and the degree to which third party payors approve the tests for reimbursement . 57 additional funding may not be available to us on acceptable terms or at all . in addition , the terms of any financing may adversely affect the holdings or the rights of our stockholders . for example , if we raise additional funds by issuing equity securities or by selling debt securities , if convertible , further dilution to our existing stockholders would result . to the extent our capital resources are insufficient to meet our future capital requirements , we will need to finance our future cash needs through public or private equity offerings , collaboration agreements , debt financings or licensing arrangements . if adequate funds are not available , we may be required to terminate , significantly modify or delay our development programs , reduce our planned commercialization efforts , or obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently . further , we may elect to raise additional funds even before we need them if we believe the conditions for raising capital are favorable . off-balance sheet arrangements we do not currently have , nor have we ever had , any relationships with unconsolidated entities or financial partnerships , such as entities often referred to as structured finance or special purpose entities , established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes . in addition , we do not engage in trading activities involving non-exchange traded contracts . recent accounting pronouncements in may 2014 , the financial accounting standards board ( the “ fasb ” ) issued accounting standards update ( “ asu ” ) no . 2014-09 , revenue from contracts with customers : topic 606 ( “ asu 2014-09 ” ) , to supersede nearly all existing revenue recognition guidance under u.s. gaap . the core principle of asu 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services . asu 2014-09 defines a five step process to achieve this core principle and , in doing so

